Background: Abciximab, a platelet glycoprotein IIb / IIIa receptor inhibitor, has been shown to lower mortality and myocardial reinfarction in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).